402-65-3

Basic information

• Product Name: 2-Fluoroisonicotinic acid
• Synonyms: 2-FLUORO-4-PYRIDINECARBOXYLIC ACID;2-FLUOROPYRIDINE-4-CARBOXYLIC ACID;2-FLUOROISONICOTINIC ACID;2-Fluoro-4-pyridinecarboxlic acid;2-Fluoroisonicotinic acid ,98%;4-Pyridinecarboxylic acid, 2-fluoro-;2-Fluoropyridine-4-carboxylic acid ,98%;2-Fluoropyridine-4-carboxylic acid, 4-Carboxy-2-fluoropyridine
• CAS NO: 402-65-3
• Molecular Formula: C₆H₄FNO₂
• Molecular Weight: 141.1
• EINECS: 200-589-5
• Product Categories: Nitrogen cyclic compounds;Pyridine;pharmacetical;Heterocyclic Compounds;Building Blocks;Fluoropyridines;Halopyridines;Pyridines;Picolinic acid series
• Mol File: 402-65-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 200 °C (dec.)(lit.)
• Boiling Point: 396.6 °C at 760 mmHg
• Flash Point: 193.6 °C
• Appearance: /Powder
• Density: 1.419 g/cm³
• Vapor Pressure: 0.00301mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.03±0.10(Predicted)
• CAS DataBase Reference: 2-Fluoroisonicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoroisonicotinic acid(402-65-3)
• EPA Substance Registry System: 2-Fluoroisonicotinic acid(402-65-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 402-65-3(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powder

InChI:InChI=1/C6H4FNO2/c7-5-1-4(6(9)10)2-8-3-5/h1-3H,(H,9,10)

Upstream product

• 695-34-1 2-Amino-4-methylpyridine 
• 461-87-0 2-fluoro-4-methylpyridine 

Downstream Products

• 131747-69-8 2-fluoropyridin-4-carboxyaldehyde 
• 108338-11-0 2,6-Dimethyl-4-(2-fluoro-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 123412-43-1 N-<(2-fluoropyridin-4-yl)carbonyl>pyrrolidine-2-carboxylic acid 
• 131747-60-9 (2-fluoropyridin-4-yl)methanol 
• 65352-95-6 2-fluoro-pyridine-4-carboxyl chloride 
• 123412-95-3 ethyl 2-fluoroisonicotinate 
• 455-69-6 2-fluoro-isonicotinic acid methyl ester 
• 1187669-35-7 4-(2-fluoro-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-32-4 2-bromo-1-(2-methoxypyridin-4-yl)ethanone 
• 764708-20-5 1-(2-methoxypyridin-4-yl)ethanone 
• 111887-72-0 1-(2-fluoropyridin-4-yl)ethan-1-one 

Relevant articles and documents

Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: New multimodal fluorinated and iodinated radiotracers

This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (123I, 124I, 18F) and systemic treatment (131I) of melanoma potentialities. The biodistribution of each 125I-labeled tracer was evaluated in a model of melanoma B16F0-bearing mice, using in vivo serial γ scintigraphic imaging. Among this series, [125I]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [18F]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [131I]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (18F, 124I) and targeted radionuclide therapy ( 131I) of melanoma using a single chemical structure.

Rapid and efficient synthesis of [18F]fluoronicotinamides, [18F]fluoroisonicotinamides and [18F]fluorobenzamides as potential pet radiopharmaceuticals for melanoma imaging

In an attempt to simplify nucleophilic radiofluorination reactions to be amenable for automation, a series of [18F]fluoronicotinamides, [ 18F]fluoroisonicotinamides and [18F]fluorobenzamides were synthesized using one-step

CYCLOALKANOPYRIDINE DERIVATIVE

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

Substituted benzimidazoles

Compounds of formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NFκB is involved.

Bis-acyloxymethyl derivatives

This invention relates to new pyridyl, quinoline and acridine bis-acyloxymethyl compounds; to compositions comprising these compounds; and to processes for their utility as fungicides, bactericides and as inhibitors of the growth of cancer in warm-blooded animals. In accordance with this invention, new bis-acyloxymethyl derivatives are provided of the formula: STR1 wherein B is selected from substituted and unsubstituted alkyl, cycloalkyl, aryl, alkenyl, cycloalkenyl and alkynyl; A is selected from hydrogen and B; or, A and B together comprise a pyrrolizine; L is selected from STR2 wherein Y is selected from hydrogen or STR3 each R and Z is independently selected from hydrogen or substituted and unsubstituted alkyl, cycloalkyl, aryl, alkenyl, cycloalkenyl, alkynyl, amine group, each Z' is independently selected from hydrogen and substituted or unsubstituted alkyl; M is Z or is selected from halogen, nitro, hydroxyl, nitrile and substituted or unsubstituted, carboxylic acid group, carboxylic acid ester group, carboxylic acid amide group, sulfonic acid group and sulfonic acid amide group; ether group, thioether group, acylated hydroxyl, sulfonylamide, sulfonylurea, sulfoxide group, sulfone group and mixtures thereof; each n is the same and is 0 or 1; q is from 0-4; and, X is the anion of an acid.

Synthesis, Chemistry, and Antineoplastic Activity of α-Halopyridinium Salts: Potential Pyridone Prodrugs of Acylated Vinylogous Carbinolamine Tumor Inhibitors

A series of 4- and 5-methyl>-1H-pyrrolizin-5-yl>-2-halopyridinium iodides were synthesized.The rates of hydrolysis of the α-halopyridinium salts to the corresponding pyridones, and the reactivities of the carbamate moieties were studied as a function of pH, buffer composition, and ionic strength.The 4- and 5-pyrrolizinyl-2-halopyridinium iodides and the corresponding pyridones were evaluated against P388 lymphocytic leukemia in vivo.The α-fluoropyridinium compounds were active but the α-chloro compounds were not.This activity was correlated with the rates of hydrolysis of the α-halopyridinium compounds to the active pyridone.Compounds that were active in the P388 screen were evaluated in L1210 leukemia, M5076 carcinoma, and MX-1 mammary xenograft assays in mice.